Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLiquidia Technologies Inc

Liquidia Technologies Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
44.4 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1291167
Market Cap
5882.52M
P/E
46.94

Momentum Score

…

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
44.23
Low
45.69
High
52 Week Price Range
21.14
Low
93.61
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Liquidia Technologies is a clinical-stage biotech using its PRINT particle-engineering platform to develop inhaled therapies, with a lead dry‑powder treprostinil candidate for pulmonary arterial hypertension. Long-term growth drivers include regulatory approval and commercialization of the lead program, potential expansion into additional pulmonary indications, and partnerships to scale the platform; the company appears positioned to offer differentiated inhaled delivery that could improve dosing convenience.
The principal risks are clinical and regulatory failure, limited cash runway and commercialization execution against established competitors; investors should monitor trial results and financing milestones.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
44.40
Dividend Yield
-
Revenue TTM
450.91M
Revenue Per Share
5.15
Gross Profit TTM
417.28M
Debt / Equity
4.42
ROE
131.82%
Net Debt
7.25M
ROCE
-23.29%
Diluted EPS TTM
1.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -68.92M -130.39M -78.50M -41.02M -34.58M
Net income -68.92M -130.39M -78.50M -38.37M -29.78M
Selling general administrative 157.18M 81.57M 44.74M 32.41M 23.11M
Selling and marketing expenses - - 0.78M - -
Gross profit 145.08M 8.12M 14.60M 13.08M 9.83M
Reconciled depreciation 1.53M 2.20M 2.24M 3.65M 5.61M
Ebit -44.75M -117.91M -72.23M -38.77M -33.80M
Ebitda -43.22M -115.71M -70.05M -37.68M -33.76M
Depreciation and amortization 1.53M 2.20M 2.18M 1.09M 0.03M
Operating income -51.38M -121.29M -73.38M -38.77M -33.80M
Other operating expenses 209.70M 135.29M 90.87M 54.70M 46.65M
Interest expense 24.17M 12.49M 6.27M 2.34M 0.82M
Interest income 6.62M 7.65M 3.18M 1.09M 0.03M
Net interest income -17.55M -4.83M -1.83M -1.25M -0.78M
Income tax expense - - -2.18M -2.65M -4.80M
Total revenue 158.32M 14.00M 17.49M 15.94M 12.85M
Total operating expenses 196.45M 129.41M 87.98M 51.85M 43.63M
Cost of revenue 13.24M 5.88M 2.89M 2.86M 3.02M
Total other income expense net -17.55M -9.10M -5.12M -2.25M -0.78M
Net income from continuing ops -68.92M -130.39M -57.59M -41.02M -34.58M
Net income applicable to common shares - - - -41.02M -34.58M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 327.93M 230.31M 120.43M 129.20M 93.73M
Intangible assets 2.95M 3.16M 3.43M 3.73M 4.39M
Other current assets -54.09M 5.67M 2.16M 1.51M 0.79M
Total liab 283.19M 153.04M 73.14M 38.78M 28.46M
Total stockholder equity 44.75M 77.28M 47.29M -350.60M -309.58M
Deferred long term liab - - - 8.60M 10.14M
Other current liab 73.20M 18.66M 16.02M 5.52M 5.17M
Common stock 0.09M 0.09M 0.07M 0.06M 0.05M
Capital stock 0.09M 0.09M 0.07M 0.06M 0.05M
Retained earnings -626.31M -559.49M -429.10M -350.60M -309.58M
Other liab - - - 6.59M 6.14M
Good will 3.90M 3.90M 3.90M 3.90M 3.90M
Other assets - - 0.00M 129.20M 16.73M
Cash 190.68M 176.48M 83.68M 93.28M 57.49M
Total current liabilities 135.77M 41.78M 18.55M 8.80M 7.33M
Net debt 7.25M -54.09M -80.18M -68.82M -41.42M
Short term debt 58.89M 18.43M 1.14M 1.08M 1.09M
Short long term debt 58.41M 18.02M - - -
Short long term debt total 197.93M 122.39M 3.50M 24.46M 16.08M
Other stockholder equity 670.97M 636.68M 476.32M -0.06M -0.05M
Property plant equipment - - - 6.25M 7.43M
Total current assets 190.68M 185.10M 89.90M 99.81M 61.28M
Net tangible assets - - - 82.79M 56.97M
Net receivables 54.09M 2.72M 4.06M 5.02M 2.99M
Long term debt 132.94M 97.37M - 19.88M 10.41M
Inventory 23.80M 0.24M 0.00M - -
Accounts payable 3.68M 4.69M 1.40M 2.20M 1.07M
Non currrent assets other 126.89M 25.66M 14.92M 15.51M 16.73M
Non current assets total 137.25M 45.21M 30.53M 29.39M 32.45M
Capital lease obligations 6.59M 7.00M 3.50M 4.58M 5.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -8.44M -11.57M -0.59M -0.11M
Change to liabilities - - - 0.81M -7.56M
Total cashflows from investing activities -6.34M -8.44M -11.29M -0.59M -0.11M
Net borrowings 53.82M 52.50M 17.72M 8.96M -0.42M
Total cash from financing activities 59.73M 194.66M 43.25M 64.96M 26.32M
Change to operating activities - - - -0.94M -1.83M
Net income -68.92M -130.39M -78.50M -41.02M -34.58M
Change in cash 14.20M 92.80M -9.60M 35.79M -7.82M
Begin period cash flow 176.48M 83.68M 93.28M 57.49M 65.32M
End period cash flow 190.68M 176.48M 83.68M 93.28M 57.49M
Total cash from operating activities -35.69M -93.42M -41.56M -28.59M -34.04M
Issuance of capital stock 0.00M 138.55M 24.24M 54.46M 21.71M
Depreciation 1.53M 2.20M 2.18M 3.65M 5.61M
Other cashflows from investing activities -2.00M -3.49M -10.00M - -
Change to inventory -22.99M -0.24M 0.00M - -1.73M
Change to account receivables -51.37M 1.34M 0.96M -2.03M -2.99M
Other cashflows from financing activities 1.08M 3.61M -0.36M 21.31M 15.44M
Change to netincome - - - 10.94M 7.31M
Capital expenditures 4.34M 4.95M 1.29M 0.59M 0.11M
Change in working capital -24.18M -4.79M 5.87M -2.16M -12.38M
Stock based compensation 29.47M 18.81M 10.09M 9.30M 6.75M
Other non cash items 26.42M 20.76M 18.80M 1.64M 0.52M
Free cash flow -40.02M -98.37M -42.85M -29.18M -34.14M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LQDA
Liquidia Technologies Inc		 -
-%		 44.40 46.94 10.19 13.05 29.97 12.74 32.31
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Liquidia Technologies Inc

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

419 Davis Drive, Morrisville, NC, United States, 27560

919 328 4400

https://www.liquidia.com

216

Name Title Year Born
Dr. Roger A. Jeffs Ph.D. CEO & Director 1962
Mr. Robert A. Lippe Chief Operations Officer 1965
Dr. Tushar Shah M.D. Sr. VP of Product Devel. 1961
Mr. William R. Kenan Jr. Co-Founder NA
Dr. Ginger Denison Co-Founder NA
Mr. Michael Kaseta Chief Financial Officer 1976
Jennifer Almond Director of Investor Relations & Corp. Communications NA
Mr. Russell Schundler Gen. Counsel & Corp. Sec. 1975
Mr. Jason Adair Sr. VP of Corp. Devel. & Strategy 1974
Ms. Celia Reyes-Hoke VP of People & Culture NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…